Werner Milton H.'s Form 4 filing
Inhibikase Therapeutics, Inc. (IKT) · filed Nov 19, 2021
- Accession no.
- 0001104659-21-141628
- Filed
- Nov 19, 2021
- Trade date
- Nov 17, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market purchases total $46.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Werner Milton H.CIK 0001827621 | Director, Officer (President and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2021 | Common Stock | PPurchaseAcquired | +17,569 | $1.98 | +$34,786.62 | 23,589 | Indirect | |
| Nov 17, 2021 | Common Stock | PPurchaseAcquired | +1,100 | $1.97 | +$2,167 | 23,589 | Indirect | |
| Nov 17, 2021 | Common Stock | PPurchaseAcquired | +3,186 | $1.96 | +$6,244.56 | 23,589 | Indirect | |
| Nov 17, 2021 | Common Stock | PPurchaseAcquired | +1,334 | $1.94 | +$2,587.96 | 23,589 | Indirect | |
| Nov 17, 2021 | Common Stock | PPurchaseAcquired | +400 | $1.93 | +$772 | 23,589 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.